Your browser doesn't support javascript.
loading
Current Status and Progress of Thermal Ablation Combined with Immunotherapy for Lung Tumors / 中国肺癌杂志
Chinese Journal of Lung Cancer ; (12): 266-271, 2022.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-928808
Biblioteca responsável: WPRO
ABSTRACT
Recent studies have shown that tumor immune microenvironment is closely related to tumor progression, metastasis, recurrence and response to treatment. Some immunotherapies also offer hope for cancer patients. However, the efficacy of tumor immunotherapy is uncertain and has some side effects. In order to enhance its efficacy, tumor immunotherapy combined with tumor thermal ablation has been studied. Thermal ablation has the advantages of minimally invasive, rapid recovery, safety, fewer complications, conformation, reliable effect, repeatable, low cost, and has become the fourth tumor treatment measure after surgery, radiotherapy, and drug therapy. It can directly kill tumor cells and modulate the immune system through a variety of mechanisms, although the corresponding mechanisms are not well understood, but combined tumor immunotherapy has been proposed to treat several solid malignancies. In this review, the current status and progress of thermal ablation combined with immunotherapy for lung tumor were reviewed, and further studies on the efficacy and safety of thermal ablation combined with immunotherapy were expected.
.
Assuntos

Texto completo: Disponível Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Terapia Combinada / Microambiente Tumoral / Hipertermia Induzida / Imunoterapia / Neoplasias Pulmonares Limite: Humanos Idioma: Chinês Revista: Chinese Journal of Lung Cancer Ano de publicação: 2022 Tipo de documento: Artigo
Texto completo: Disponível Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Terapia Combinada / Microambiente Tumoral / Hipertermia Induzida / Imunoterapia / Neoplasias Pulmonares Limite: Humanos Idioma: Chinês Revista: Chinese Journal of Lung Cancer Ano de publicação: 2022 Tipo de documento: Artigo
...